17 November 2026

# NeuroStrip registered as a Medical Device in Australia

NeuroStrip is included in the Australian Register of Therapeutic Goods as a Class I medical device, enabling supply in Australia.

**Control Bionics Limited (ASX: CBL) (Control Bionics or the Company) advises that NeuroStrip, its wearable surface electromyography (sEMG) device, has been included in the Australian Register of Therapeutic Goods (ARTG) by the Therapeutic Goods Administration (TGA).**

## Highlights

- NeuroStrip was included in the ARTG on 16 November 2026 as a Class I medical device (ARTG 533480).
- ARTG inclusion allows Control Bionics to supply NeuroStrip in Australia immediately.
- NeuroStrip now has regulatory registrations in the US, Great Britain, the EU and Australia.

Control Bionics CEO and Managing Director Jeremy Steele said: “TGA inclusion means we can now supply NeuroStrip in Australia, our home market. It complements our registrations in the US, Europe and the UK, so the NeuroStrip is now registered in four major markets. Customers and partners expect this regulatory foundation to commence utilising the NeuroStrip and the platform. Our focus is on winning customers and partners in each of them.”

## What ARTG Inclusion Means

ARTG inclusion enables NeuroStrip, together with the NeuroStrip.IQ app, already available through the Apple App Store, Mac App Store and Microsoft Store, to be supplied to clinicians, rehabilitation providers, researchers and sports organisations in Australia.

NeuroStrip is included as a Class I medical device, reflecting its intended purpose as a non-diagnostic sEMG measurement and biofeedback tool. Inclusion of a Class I device is based on the sponsor’s certification under section 41FD of the Therapeutic Goods Act 1989 that the device meets the applicable requirements.

## NeuroStrip Regulatory Position at 17 November 2026

| Market | Status | Date |
|---|---|---|
| United States | FDA establishment registration and device listing | August 2026 |
| Great Britain | MHRA manufacturer and device registration. UKCA marking | 6 August 2026 |
| European Union, EEA and Northern Ireland | EU MDR Declaration of Conformity issued. Class I. Registration completed | 2 October 2026 |
| Australia | Included in the ARTG. Class I. ARTG 533480 | 16 November 2026 |

## Authorisation

This announcement has been authorised for release to the ASX by the Board of Control Bionics Limited.

Jeremy Steele
CEO and Managing Director
jsteele@controlbionics.com

Brett Crowley
Company Secretary
brettcrowley@controlbionics.com

# About Control Bionics

Control Bionics Limited is a neurotechnology company commercialising objective, non-invasive neural-signal technology proven in clinical environments and built to scale across multiple markets. Its neural-signal platform captures the body's physiological signals, including the electrical activity generated by muscles, with medical-grade precision and converts them into measurable, decision-ready outcomes. A single underlying technology platform serves four applications: Performance, Rehabilitation, Research & Data, and Assistive Communication. The technology has historically been deployed in assistive communication and is now being extended into sports performance, rehabilitation, medical research, platform partnerships and broader human-computer interface applications. Control Bionics' technology does not require surgery or implantation, and holds regulatory clearances in the US, Australia and Europe. The Company is also a registered NDIS provider in Australia.